Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Large Drop in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 276,200 shares, a decrease of 30.2% from the September 30th total of 395,900 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 0.2 days. Approximately 5.0% of the company’s shares are short sold. Approximately 5.0% of the company’s shares are short sold. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 0.2 days.

Liminatus Pharma Price Performance

NASDAQ:LIMN traded down $0.07 during trading hours on Monday, reaching $1.32. 280,603 shares of the stock were exchanged, compared to its average volume of 501,413. The stock has a 50-day simple moving average of $1.78. Liminatus Pharma has a twelve month low of $1.11 and a twelve month high of $33.66. The stock has a market cap of $35.73 million and a P/E ratio of -26.40.

Liminatus Pharma (NASDAQ:LIMN) last released its quarterly earnings results on Friday, October 3rd. The company reported ($0.05) EPS for the quarter.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liminatus Pharma in a report on Wednesday, October 8th. Wall Street Zen upgraded Liminatus Pharma from a “sell” rating to a “hold” rating in a report on Saturday, August 30th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.